Evidence map›Paper›PMID 40784773›Full record

ArticleBMJ open2025

Contributions of contrast-enhanced ultrasound (CEUS) to a fetal-placental circulation study (EVUPACUS): a protocol for a prospective comparative study in a population of women undergoing termination of pregnancy.

Juliette Lefebvre, Aboubaker Cherifi, Gabriela Hossu, Anne-Laure Fijean, Olivier Morel, Charline Bertholdt, Marine Beaumont, Matthieu Dap

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06497959 (Contribution of Contrast-Enhanced Ultrasound), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06497959 phase3recruitingnot on this map

Contribution of Contrast-Enhanced Ultrasound (CES) in the Fetal-placental Circulation Study

TypeinterventionalSponsorCentral Hospital, Nancy, FranceRan2025 to 2029Enrolled30ConditionsFetal Growth RestrictionArmsSonoVue
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juliette LefebvreDepartment of Obstetrics and Fetal Medicine, Nancy University Hospital, Nancy, France.ORCID http://orcid.org/0000-0003-0107-9868
Aboubaker CherifiCIC, Innovation Technologique, Université de Lorraine, Nancy University Hospital, Nancy, France.
Gabriela HossuIADI INSERM-U1254, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Anne-Laure FijeanDepartment of Obstetrics and Fetal Medicine, Nancy University Hospital, Nancy, France.ORCID http://orcid.org/0000-0002-3547-9889
Olivier MorelDepartment of Obstetrics and Fetal Medicine, Nancy University Hospital, Nancy, France.
Charline BertholdtDepartment of Obstetrics and Fetal Medicine, Nancy University Hospital, Nancy, France.
Marine BeaumontCIC, Innovation Technologique, Université de Lorraine, Nancy University Hospital, Nancy, France.
Matthieu DapDepartment of Obstetrics and Fetal Medicine, Nancy University Hospital, Nancy, France m.dap@chru-nancy.fr.ORCID http://orcid.org/0000-0002-2846-1509

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPre-eclampsia and fetal growth restriction (FGR) are two principal complications of pregnancy related to placental dysfunction. Nevertheless, knowledge of the underlying pathophysiological mechanisms remains inadequate, and only a few tools are available for in vivo assessment of placental perfusion. Contrast-enhanced ultrasound (CEUS) allows organ vascularisation evaluation via a strictly intravascular gas microbubble. The primary aim of this study is to compare placental vascularisation parameters obtained via CEUS between pregnancies with FGR and those without FGR. METHODS AND ANALYSIS: This is a single-centre, prospective, comparative, non-randomised, feasible, open and interventional study. We will include 30 women with medical termination of pregnancy divided into two groups: one with severe FGR and the other without FGR. Severe FGR is defined as an estimated fetal weight below the third percentile for gestational age. Women will be informed and recruited in the fetal medicine unit over a period of 48 months. The primary goal of this study is to compare the placental contrast ultrasound parameter measurements according to group. The primary objective is to compare placental contrast ultrasound data in women who undergo medical termination of pregnancy at a gestational age of 16 weeks (38+6 days) between two groups: a group with FGR and a group without FGR. The secondary objectives are as follows: (1) to describe the placental vascularisation parameters measured by CEUS; (2) to describe the parameters for quantifying vascularisation at different gestational ages via CEUS; (3) to study the associations between CEUS data and placental histological data and (4) to establish a biological collection of placentas to increase our knowledge of the development and functions of the placenta during pregnancy. The statistical analysis will include descriptive analysis for all study patients, with quantitative data described by means±SDs, medians, IQRs, and extreme values and qualitative data reported as counts and percentages. Comparisons of placental contrast ultrasound parameters between the two groups will be performed via Student's t-test or the Mann-Whitney U test on the basis of data normality. Associations between CEUS parameters and placental histology data will be analysed with Spearman or Pearson correlations. Qualitative associations will be studied via analysis of variance or the Kruskal-Wallis test. Box plot representations will be used when applicable. Analyses will be performed with R software, with significance set at p<0.05. ETHICS AND DISSEMINATION: This study was approved by the French Ethics Committee, the CPP (Comité de Protection des Personnes) SUD EST II - LYON - FRANCE, on 26 April 2024, with reference number 2023-506936-34-00, and the competent authority ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) authorised the study on 17 May 2024. The results of this study will be published in a peer-reviewed journal and will be presented at relevant conferences. TRIAL REGISTRATION NUMBERS: NCT06497959; EU CT number: 2023-506936-34-00.

Indexed as

Abortion, InducedFetal Growth RetardationPlacentaPlacental CirculationUltrasonography, PrenatalAdultContrast MediaFeasibility StudiesFemaleGestational AgeHumansNon-Randomized Controlled Trials as TopicPre-EclampsiaPregnancyProspective StudiesContrast MediaFetal medicinePrenatal diagnosisULTRASONOGRAPHY

Identifiers

PMID40784773
PMCPMC12336553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.